[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100313082":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":20,"locations":25,"responsibleParty":39,"collaborators":20,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":20,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":20,"enrollmentInfo":50,"targetDuration":20,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":65,"whyStopped":20,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"GlaxoSmithKline","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"HPV Group","EXPERIMENTAL","Healthy Chinese female subjects, including and above 17 years of age at the time of enrollment, who received all three doses of the Cervarix vaccine in the HPV-058 (NCT00996125) primary study.",[13],"Procedure: Blood sampling for antibody determination",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","Blood sampling for antibody determination","In order to assess the persistence of immune responses seven to eight years after the last vaccine dose against HPV-16\u002F18, a blood sample (\\~5 mL) will be taken from all the subjects, at Day 1.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"GSK Clinical Trials","STUDY_DIRECTOR",[26],{"facility":27,"status":20,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":20},"GSK Investigational Site","Taizhou","Jiangsu","225300","China","CN",{"type":34,"coordinates":35},"Point",[36,37],119.90812,32.49069,{"lat":37,"lon":36},{"type":40,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100313082","phase-3-a-follow-up-extension-study-to-evaluate-the-persistence-of-immune-response-to-gsk-biologicals-hpv-vaccine-in-healthy-chinese-female-subjects-who-received-three-doses-of-the-vaccine-in-the-hpv-058-study-100313082",true,"NCT03355820","A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study","Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects From the HPV-058 Study","Inclusion Criteria:\n\n* Subjects\u002Fsubject's parents\u002Flegally acceptable representative(s) \\[LAR(s)\\] who, in the opinion of the investigator, can and will comply with the requirements of the protocol.\n* Written informed consent obtained from the subject or subject's parents\u002FLAR(s) prior to performing any study specific procedure.\n* Written informed assent obtained from the subjects below the legal age of consent.\n* Subjects who received all three doses of the HPV-16\u002F18 vaccine in the HPV-058 study.\n* Healthy subjects as established by medical history and clinical examination before entering into the study.\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product (drug or vaccine which may have an impact on the study objectives) during the period starting 30 days (Day 29 to Day 1) before the study visit.\n* Concurrently participating in another clinical study, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine\u002Fproduct (pharmaceutical product or device).\n* Previous vaccination against HPV outside the HPV-058 study.\n* Subjects with contraindications related to blood draw such as blood disorders and anticoagulants use.","FEMALE","17 Years",{"count":51,"type":52},228,"ACTUAL","INTERVENTIONAL",[55],"PHASE3","The purpose of this study is to evaluate the persistence of immune response in subjects who received the HPV-16\u002F18 vaccine, seven to eight years after the last dose of primary vaccination in the HPV-058 study. No new subjects will be enrolled in this extension study.",[58],"Cervical Intraepithelial Neoplasia",[60,61,62,63,64],"Immune response","Cervarix","Persistence","Chinese","Human papillomavirus","COMPLETED","2020-10-27",{"date":68,"type":52},"2020-11-19",{"date":70,"type":52},"2018-02-28",{"date":72,"type":52},"2018-06-29",{"name":5,"class":6},1]